スリーエムに関するコメント

April 2024 has been a remarkable month for my portfolio, characterized by a surge that edge out the $Hang Seng Index(800000.HK)$ by a hair's breadth, but outpaced major benchmarks like $SPDR S&P 500 ETF(SPY.US)$ and $FTSE Singapore Straits Time Index(.STI.SG)$.
One of the main reasons behind this performance was long awaited rally in the Chinese market. After weathering 3 years of turbulent crashes, it was like seeing a phoenix r...

The market rebounded into the green but fell back to the mixed bag it had traded at all day following the FOMC's no-change rate decision and Federal Reserve President Jerome Powell's Press conference.
The $S&P 500 Index(.SPX.US)$ traded -0.34% after just after close, while the $NYダウ(.DJI.US)$ climbed +0.23% and the $Nasdaq Composite Index(.IXIC.US)$ gained -0.33%.
MACRO
Wednesday, the Federal Open Market Committee left the ...

Morning mooers! It is Wednesday, May 1st, and the market is mixed, halfway through a packed Q1 earnings week and awaiting the FOMC rate decision this afternoon.
My name is Kevin Travers, and the sun is coming out in Jersey City, here are your morning moovers:
Mooers, what are you watching today? Comment below and I may feature your comment tomorrow!
MOOVERS
Recent earnings pulled down the S&P500. Shares of $CVS Health (CVS.US)$ tumbled...

$スリーエム(MMM.US)$ before spin off 125 to 130.

Morning mooers! It is Tuesday, April 30th, and the market is in red on the second day of jam-packed Q1 earnings week. Mooers, what are you watching today? Comment below and I may feature your comment tomorrow!
My name is Kevin Travers, and the city is foggy with mixed earnings results, here are stories moooving the market:
MOOVERS
$Eli Lilly and Co (LLY.US)$ rose 7% after the drug maker reported a 26% increase in quarterly revenue, aided by ro...

Morning Movers
Gapping up
$イーライ リリィ(LLY.US)$ The pharmaceutical company's stock increased by 6.7% following its report of stronger-than-expected earnings for the first quarter and raised its full-year guidance, fueled by robust sales of its diabetes medication Mounjaro and the newly released weight loss treatment Zepbound.
$スリーエム(MMM.US)$ The industrial conglomerate's shares jumped 7.4% after surpassing analysts' expectation...